<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150670</url>
  </required_header>
  <id_info>
    <org_study_id>91023039</org_study_id>
    <nct_id>NCT00150670</nct_id>
  </id_info>
  <brief_title>Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer</brief_title>
  <official_title>Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This study aimed to verify the survival benefit of TS-1 plus CDDP combination chemotherapy
      compared with the monotherapy by TS-1 alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled, open-label, parallel, multicenter study. Patients are
      stratified according to 3 factors ; performance status (ECOG scale: 0, 1, 2), disease stage
      (unresectable gastric cancer or recurrent gastric cancer (received prior adjuvant
      chemotherapy or not)) and participating center. Patients are randomized to one of two
      treatment arms. Arm A: Patients receive oral TS-1 twice daily on days 1-28 followed by 14
      days rest. Treatment is repeated every 42 days for up to 4 courses. Arm B: Patients receive
      CDDP iv on day 8 and oral TS-1 twice daily on days 1-21 followed by 14 days rest. Treatment
      is repeated every 35 days for up to 5 courses. Patients are followed every 6 months for up to
      2 years from the day they participates in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every course for first three courses, then every other course</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate, lesion-directed response rate, time to treatment failure (TTF), hospitalization-free survival period within the periods of TTF, and safety profile</measure>
    <time_frame>every course for first three courses, then every other course</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment>300</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TS-1 and cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TS-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-1 and cisplatin</intervention_name>
    <description>TS-1(40-60 mg per body surface area) was given orally, twice daily for 3 consecutive weeks, and 60 mg/m2 cisplatin was given intravenously on day 8, followed by a 2-week rest period, within a 5-week cycle.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-1</intervention_name>
    <description>TS-1(40-60 mg per body surface area) was given orally, twice daily for 4 consecutive weeks, followed by a 2-week rest period, within a 6-week cycle.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma

          -  Unresectable and recurrent gastric cancer

          -  Age 20 to 74

          -  Performance status 0, 1, or 2 (ECOG)

          -  Life expectancy 3 months

          -  No prior chemotherapy or radiotherapy for gastric cancer

          -  Able to take oral medication

          -  Evaluable or not evaluable lesion had already checked more than 28 days before
             participated in this study

          -  Hematopoietic Absolute granulocyte count lower limit of normal-12,000/mm^3 Platelet ≥
             100,000/mm^3 Hemoglobin ≥ 8.0 g/dL

          -  Hepatic AST and ALT ≤ 100 U/L ALP ≤ 2 times upper limit of normal (ULN) Bilirubin ≤
             1.5 mg/dL

          -  Renal Plasma creatinine ≤ ULN Creatinine clearance ≥ 50 mL/min

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Bleeding from gastrointestinal tract or no diarrhea

          -  Hypersensitivity to TS-1 or CDDP

          -  Psychiatric disorder that would preclude study compliance or giving informed consent

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality

          -  Serious illness or medical condition

          -  Brain metastasis

          -  Ascites requiring drainage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wasaburo Koizumi, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Hospital, Kitasato University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>East Hospital, Kitasato University</name>
      <address>
        <city>2-1-1, Asamizodai, Sagamihara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008 Mar;9(3):215-21. doi: 10.1016/S1470-2045(08)70035-4. Epub 2008 Feb 20.</citation>
    <PMID>18282805</PMID>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>July 6, 2011</last_update_submitted>
  <last_update_submitted_qc>July 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Taiho Pharmaceutical Co., Ltd.</name_title>
    <organization>Taiho Pharmaceutical Co., Ltd.</organization>
  </responsible_party>
  <keyword>Stomach cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

